Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021;11(s2):S141-S145.
doi: 10.3233/JPD-212650.

Bringing Advanced Therapies for Parkinson's Disease to the Clinic: The Patient's Perspective

Affiliations
Review

Bringing Advanced Therapies for Parkinson's Disease to the Clinic: The Patient's Perspective

Soania Mathur et al. J Parkinsons Dis. 2021.

Abstract

There is an urgent unmet need in the Parkinson's disease community-advanced therapies to modify the inevitable decline that occurs in those affected by this progressive neurodegenerative disease for which there is no cure. This will require collaboration from all stakeholders and central to those partnerships are patients themselves. But participation in clinical trials and clinical use of advanced therapies have their own risk profile above and beyond standard therapeutics as evidenced by past invasive procedures. Therefore, it is of utmost importance that clear, evidence-based information about these potential treatments be clearly communicated by those exploring their use to ensure safe and informed participation from the patient community. Likewise, patients must weigh the benefits of these treatments their limitations and risks in order to truly give informed consent to participate in bringing these treatments to the clinic. Here we explore these issues from the patient perspective.

Keywords: Parkinson’s disease; advanced treatments; clinical research; gene therapy; patient risk; patient-centered; recruitment; stem cell replacement.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interest to report.

Similar articles

Cited by

References

    1. Parkinson J (1817) An essay on the shaking palsy. Printed by Whittingham & Rowland, London.
    1. Wirdefeldt K, Odin P, Nyholm D (2016) Levodopa-carbidopa intestinal gel in patients with Parkinson’s disease: A systematic review. CNS Drugs 30, 381–404. - PubMed
    1. Moosa S, Martínez-Fernáandez R, Elias WJ, Del Alamo M, Eisenberg HM, Fishman PS (2019) The role of high-intensity focused ultrasound as a symptomatic treatment for Parkinson’s disease. Mov Disord 34, 1243–1251. - PubMed
    1. Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, Henriksen T, van Laar T, Spivey K, Vel S, Staines H, Lees A (2018) Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations (TOLEDO): A multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol 17, 749–759. - PubMed
    1. McFarthing K, Buff S, Rafaloff G, Dominey T, Wyse RK, Stott SRW (2020) Parkinson’s disease drug therapies in the clinical trial pipeline: 2020. J Parkinsons Dis 10, 757–774. - PMC - PubMed